Product Description
Jiayue Pharmaceutical has developed JYP-0061, an oral approved drug to treat a variety of autoimmune diseases such as RA. (Sourced from: http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic|Neuromyelitis Optica
Phase 1: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06697535 |
JYP0061M202 | P2 |
Recruiting |
Neuromyelitis Optica |
2026-02-28 |
2024-11-21 |
Primary Endpoints |
|
NCT06158490 |
JYP0061M210 | P2 |
Enrolling by invitation |
Dermatitis, Atopic |
2026-02-10 |
2025-03-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
CTR20212321 |
CTR20212321 | P1 |
Active, not recruiting |
Arthritis, Rheumatoid |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20233559 |
CTR20233559 | P2 |
Recruiting |
Dermatitis, Atopic |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|